Carbon Footprint Associated With Severe Asthma Care Before and After Benralizumab Initiation: BENEFIT Study
Author(s)
Arnaud Bourdin, Pr1, Mandy Nizard, PhD2, Anaïs Hamon, MPH2, Diana Ayinde, PhD2, Delphine Leynaud, MPH3, Nadège Bornier, MPH4, Manon Belhassen, MPH, PhD4, Erika Guyot, PhD4, Gilles Devouaasoux, Pr5.
1CHU de Montpellier, Montpellier, France, 2AstraZeneca, Courbevoie, France, 3Astrazeneca, Courbevoie, France, 4PELyon, Lyon, France, 5Croix-Rousse Hospital-HCL, Lyon, France.
1CHU de Montpellier, Montpellier, France, 2AstraZeneca, Courbevoie, France, 3Astrazeneca, Courbevoie, France, 4PELyon, Lyon, France, 5Croix-Rousse Hospital-HCL, Lyon, France.
OBJECTIVES: Benralizumab efficacy in patients (pts) with severe asthma (SA) had been described but its ecological impact on healthcare management is unknown.The aim is to describe and compare the carbon impact of SA care 12mo before and after benralizumab initiation.
METHODS: This French health claims database study included SA adult pts with at least 1 benralizumab dispensing between 01/01/2019 and 12/31/2023. For pts with at least 12 months of follow-up, the carbon footprint associated with SA management was compared using a Wilcoxon test for the 12mo before and after the initiation of benralizumab. Carbon emission values from the literature were assigned to asthma therapies, consultations, asthma-related hospital stays, emergency room visits, medical procedures, biological acts and transport.
RESULTS: This primary analysis included 8,270 pts (59.0% female, mean age 58.7 ± 15.2 years). The mean difference [95%CI] in carbon footprint (kgCO2e) between the 12mo before and after the initiation of benralizumab, was -19.9 [-22.7; -17.2] for medications, -25.5 [-28.8; -22.3] for asthma-related hospitalizations, -4.1 [-5.0; -3.2] for emergency room visits, and -20.5 [-21.8; -19.2] for medical procedures but consultations and visits increased (mean difference [95%CI]: 22.8 [16.7; 28.9]), mainly due to an increase in nursing visits (mean difference [95%CI]: 24.2 [19.4; 28.9]). The total carbon footprint was 595.7 ± 562.6 before vs 544.0 ± 587.0 after benralizumab initiation, resulting in a mean difference of -51.6 [-59.8; -43.4]. All p<0.0001.
CONCLUSIONS: In pts treated with benralizumab there was a reduction in the ecological impact of SA care by significantly reducing the overall carbon footprint.
METHODS: This French health claims database study included SA adult pts with at least 1 benralizumab dispensing between 01/01/2019 and 12/31/2023. For pts with at least 12 months of follow-up, the carbon footprint associated with SA management was compared using a Wilcoxon test for the 12mo before and after the initiation of benralizumab. Carbon emission values from the literature were assigned to asthma therapies, consultations, asthma-related hospital stays, emergency room visits, medical procedures, biological acts and transport.
RESULTS: This primary analysis included 8,270 pts (59.0% female, mean age 58.7 ± 15.2 years). The mean difference [95%CI] in carbon footprint (kgCO2e) between the 12mo before and after the initiation of benralizumab, was -19.9 [-22.7; -17.2] for medications, -25.5 [-28.8; -22.3] for asthma-related hospitalizations, -4.1 [-5.0; -3.2] for emergency room visits, and -20.5 [-21.8; -19.2] for medical procedures but consultations and visits increased (mean difference [95%CI]: 22.8 [16.7; 28.9]), mainly due to an increase in nursing visits (mean difference [95%CI]: 24.2 [19.4; 28.9]). The total carbon footprint was 595.7 ± 562.6 before vs 544.0 ± 587.0 after benralizumab initiation, resulting in a mean difference of -51.6 [-59.8; -43.4]. All p<0.0001.
CONCLUSIONS: In pts treated with benralizumab there was a reduction in the ecological impact of SA care by significantly reducing the overall carbon footprint.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
P34
Topic
Epidemiology & Public Health, Study Approaches
Topic Subcategory
Public Health
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)